Arctic Therapeutics hf.

Address: Bjargargata 1

Sponsor Overview

assignment

Specializations

Dermatology

Arctic Therapeutics hf. supports clinical research in acne vulgaris, with interest in topical treatment approaches that address inflammatory and non-inflammatory skin lesions, as well as clinical assessment of visible disease improvement.

Acne vulgaris
Topical therapy
Inflammatory lesions
Non-inflammatory lesions

Its dermatology portfolio centers on treatment evaluation in adult patients with active facial and truncal skin disease.

Neurodegenerative disease

The sponsor is involved in research for Alzheimer’s disease, with a focus on neurological safety, brain imaging findings, and biomarkers linked to disease-related changes in the central nervous system.

Alzheimer’s disease
MRI imaging
ARIA H
ARIA E

This area reflects interest in clinical monitoring of neurodegenerative pathology and treatment-related brain effects.

Rare amyloid disorders

Arctic Therapeutics hf. also funds studies in hereditary cystatin C amyloid angiopathy (HCCAA), a rare condition associated with cerebral bleeding risk and systemic amyloid-related pathology.

Hereditary cystatin C amyloid angiopathy (HCCAA)
Cerebral bleeding events
Amyloid-cystatin C complexes
Biomarker analysis

Research in this field includes clinical and tissue-based evaluation of amyloid burden and vascular complications.

Biomarker and translational research

Across its active studies, the company places emphasis on biomarker-based assessment, including skin-derived markers, protein aggregation measures, and laboratory methods used to track biological response.

Skin biopsy biomarkers
Collagen-related markers
Cell surface activation markers
Protein aggregation

This research area links clinical outcomes with measurable molecular changes in both skin and neurological disease settings.

Trial Name	Country	Status
A phase 2 randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of topical AT-004 1% in the participants with acne vulgaris.	Denmark	Not Recruiting
Evaluation of Acetylcysteine Amide in Hereditary Cystatin C Amyloid Angiopathy: Safety, Tolerability, and Efficacy in Patients Aged 12 and Older	Iceland	Not Yet Recruiting
Evaluation of Safety, Tolerability, and Efficacy of Acetylcysteine Amide in Hereditary Cystatin C Amyloid Angiopathy Patients Aged 12 and Older	Iceland	Not Recruiting
Phase 2a Randomized, Double-Blind, Placebo-Controlled Study of N-Acetylcysteine Amide in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease	Denmark Iceland	Not Recruiting

Data & Insights

science

Molecule Portfolio

Compounds under investigation

Exclusive Molecules

out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub

Site Partnerships

Collaboration with research centres

100%

Return partnership rate

1 of 1 sites collaborated multiple times

This sponsor has worked with 1 site across their trial portfolio.

Therapeutic Focus

1.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials
165 other sponsors
2.
Nervous System Diseases1 trial
449 other sponsors
3.
Skin and Connective Tissue Diseases1 trial
247 other sponsors

Partnered Research Centres

1 centre

location_city

assignment52

Sanos A/S

Address: Boulevarden 19g, 7100 Gandrup

Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Arctic Therapeutics hf..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.